Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006
- PMID: 17318112
Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006
Abstract
Nephrogenic fibrosing dermopathy (NFD) causes thickening and hardening of the skin, often in the extremities, and occurs in patients with underlying renal disease. The skin lesions can progress rapidly, sometimes leading to joint immobility and the inability to walk. In May 2006, nephrologists at hospital A in St. Louis, Missouri, reported to CDC and the Missouri Department of Health and Senior Services (MoDHSS) a cluster of NFD among patients treated in their dialysis units. CDC and MoDHSS conducted an investigation to determine the number of affected patients and identify risk factors for NFD. Thirty-three patients with NFD were identified in St. Louis, 28 of whom had been treated at hospital A. A matched case-control study was conducted at the hospital. This report summarizes the preliminary results of that study, which indicated that exposure to gadolinium-containing contrast agents during magnetic resonance imaging (MRI) studies was independently associated with NFD. Clinicians should be aware of the potential for NFD, and when possible, should avoid use of gadolinium-containing contrast agents in patients with advanced renal disease.
Similar articles
-
Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.J Nephrol. 2008 May-Jun;21(3):324-36. J Nephrol. 2008. PMID: 18587720 Review.
-
Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.Clin Exp Dermatol. 2007 Jul;32(4):353-8. doi: 10.1111/j.1365-2230.2007.02412.x. Epub 2007 Apr 13. Clin Exp Dermatol. 2007. PMID: 17433041 Review.
-
Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study.Am J Kidney Dis. 2008 Jun;51(6):966-75. doi: 10.1053/j.ajkd.2007.12.036. Epub 2008 Mar 25. Am J Kidney Dis. 2008. PMID: 18501784
-
Gadolinium and nephrogenic systemic fibrosis: association or causation.Nephrology (Carlton). 2008 Jun;13(3):235-41. doi: 10.1111/j.1440-1797.2007.00912.x. Epub 2008 Jan 23. Nephrology (Carlton). 2008. PMID: 18221255 Review.
-
Nephrogenic systemic fibrosis in advanced chronic kidney disease: a single hospital's experience in Taiwan.Eur J Dermatol. 2009 Jan-Feb;19(1):44-9. doi: 10.1684/ejd.2008.0545. Epub 2008 Dec 5. Eur J Dermatol. 2009. PMID: 19059824
Cited by
-
N-acetylcysteine-PLGA nano-conjugate: effects on cellular toxicity and uptake of gadopentate dimeglumine.IET Nanobiotechnol. 2020 Aug;14(6):470-478. doi: 10.1049/iet-nbt.2019.0374. IET Nanobiotechnol. 2020. PMID: 32755956 Free PMC article.
-
An Updated Study to Determine Association between Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis.PLoS One. 2015 Jun 15;10(6):e0129720. doi: 10.1371/journal.pone.0129720. eCollection 2015. PLoS One. 2015. PMID: 26076348 Free PMC article.
-
Gadolinium-based contrast agents, erythropoietin and nephrogenic systemic fibrosis in patients with end-stage renal failure.NDT Plus. 2008 Jun;1(3):193-4. doi: 10.1093/ndtplus/sfn030. NDT Plus. 2008. PMID: 25983879 Free PMC article. No abstract available.
-
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.Br J Radiol. 2014 Oct;87(1042):20140307. doi: 10.1259/bjr.20140307. Br J Radiol. 2014. PMID: 25230161 Free PMC article.
-
Comparison of diagnostic accuracy of Doppler USG and contrast-enhanced magnetic resonance angiography and selective renal arteriography in patients with atherosclerotic renal artery stenosis.Med Sci Monit. 2013 Jun 19;19:475-82. doi: 10.12659/MSM.889035. Med Sci Monit. 2013. PMID: 23778330 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
